Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors

Inclusion Criteria:

Recipient procurement inclusion criteria

* Diagnosis of high-risk solid tumors: Ewing sarcoma, Wilms tumor, neuroblastoma, rhabdomyosarcoma, soft tissue sarcomas, osteosarcoma, adenocarcinoma, and esophageal carcinoma and renal cell carcinoma.
* Refractory disease, residual detectable disease following conventional therapy or relapsed disease.
* 6 months to 60 years of age at enrollment.\*
* Karnofsky/Lansky score of ≥ 50%.\*
* Absolute neutrophil count (ANC) greater than 500/µL. \*
* Absolute lymphocyte count (ALC) greater than 1000/µL.\*
* Bilirubin ≤ 2.5 mg/dL. \*
* Aspartate aminotransferase (AST)/ Alanine transaminase (ALT) ≤ 5x the upper limit of normal for age. \*
* Serum creatinine \< 1.0 mg/dL or 2 x the upper limit of normal for age (whichever is higher).\*
* Pulse oximetry of \> 90% on room air.\*
* Agree to use contraceptive measures during study protocol participation (when age appropriate).\*
* LVEF \> 50% or LVSF \> 27 % if history of total body irradiation (TBI).
* Patient or parent/guardian capable of providing informed consent.

Exclusion Criteria:

Recipient Procurement exclusion criteria

* Patients with uncontrolled infections
* Patients with active HIV
* Current evidence of GVHD \> grade 2 or chronic GVHD manifestations: bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis.
* Pregnant or lactating females
* Prior immunotherapy with an investigational agent within the last 28 days prior to procurement

Recipient Inclusion to administer cells:

* Steroids less than 0.5 mg/kg/day prednisone (or equivalent).
* Karnofsky/Lansky score of ≥ 50% %.
* Bilirubin ≤ 2.5 mg/dL.
* AST/ALT ≤ 5x the upper limit of normal for age.
* Serum creatinine \< 1.0 mg/dL or 2x the upper limit of normal for age (whichever is higher).
* Pulse oximetry of \> 90% on room air.
* Patients receiving lymphodepleting chemotherapy must have:

ANC \>750 /uL Platelet count \>75,000 /uL

Recipient Exclusion to administer cells:

* Patients with uncontrolled infections
* Patients who received ATG, Campath, or other T cell immunosuppressive monoclonal antibodies within 28 days prior to TAA-T cell infusion
* Acute GVHD \> grade 2 or chronic GVHD manifestations: bronchiolitis obliterans syndrome, sclerotic GVHD, or serositis
* Pregnant or lactating females